

## MaxCyte

### Third cohort in CARMA Phase I initiated

24 October 2019

- MaxCyte has completed the first two dose cohorts and initiated the third cohort of Phase I trial of MCY-M11, the first CARMA therapy in clinical development. No dose-limiting toxicities, infusion-related adverse events, on-target or off-target toxicities, or other safety concerns have been observed.
- The Phase I is an open-label, dose-escalation study (3+3 design) with four cohorts evaluating safety and tolerability of intraperitoneal MCY-M11 in c. 15 patients with relapsed/refractory ovarian cancer and peritoneal mesothelioma. To date, the patient cohorts have received three weekly doses of  $1 \times 10^7$  cells (Cohort 1) or  $5 \times 10^7$  cells (Cohort 2) and will now be receiving  $1 \times 10^8$  cells (Cohort 3).
- MCY-M11 is a mesothelin-targeting CARMA therapy. It is an mRNA-based chimeric antigen receptor (CAR) therapy that is wholly owned by MaxCyte. Mesothelin is expressed at normal levels on mesothelial cells, but at high levels on various tumours, including ovarian cancer.
- MaxCyte has also confirmed the feasibility of the one-day cell therapy manufacturing process, using its proprietary flow electroporation technology to transfect mRNA into fresh, unexpanded peripheral blood mononuclear cells (PBMCs).
- MaxCyte continues to explore independent funding sources for the CARMA platform.

Price	117.5p
Market Cap	£67.7m
Primary exchange	AIM London
Sector	Healthcare
Company Code	MXCT MXCS
Corporate client	Yes

#### Company description:

MaxCyte uses its patented flow electroporation platform to transfect a wide array of cells. Revenues arise from sale and lease of equipment, disposables and licence fees; with an impressive client list. Additionally, a novel mRNA mediated CAR technology, known as CARMA, is being explored in various cancers, including solid tumours.

**Trinity Delta view:** The Phase I study with the first CARMA therapy in development continues to advance to plan, which is always reassuring with a novel cell therapy, especially as the patients are receiving multiple doses of MCY-M11.

The update also confirms that the CARMA non-viral manufacturing process can be completed in 24 hours. The currently approved CAR-T therapies (Gilead/Kite's Yescarta and Novartis' Kymriah) take 7-15 days to manufacture (using viral transduction and requiring T-cell expansion). The delay between identifying a patient suitable for CAR-T therapy and being able to treat them means that the condition of many patients has deteriorated too much for them to receive the cell therapy.

We expect preliminary efficacy data from the Phase I trial to be presented at a medical conference during 2020. We believe a promising signal will be detected at the higher doses; but note this is a single agent trial without any preconditioning regimen or checkpoint inhibitor and that it will take time to optimise treatment with a CARMA therapy.

We value MaxCyte at £195m or 341p per share.

#### Analysts

##### Mick Cooper PhD

mcooper@trinitydelta.org  
+44 (0) 20 3637 5042

##### Lala Gregorek

lgregorek@trinitydelta.org  
+44 (0) 20 3637 5043

**Mick Cooper PhD CFA**

[mcooper@trinitydelta.org](mailto:mcooper@trinitydelta.org)

+44 (0) 20 3637 5042

**Lala Gregorek**

[lgregorek@trinitydelta.org](mailto:lgregorek@trinitydelta.org)

+44 (0) 20 3637 5043

**Franc Gregori**

[fgregori@trinitydelta.org](mailto:fgregori@trinitydelta.org)

+44 (0) 20 3637 5041

### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at [www.fisma.org](http://www.fisma.org). TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2019 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: [www.trinitydelta.org](http://www.trinitydelta.org)